Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2014

Open Access 01-12-2014 | Research article

Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

Authors: Ana Filipa Macedo, Ian Douglas, Liam Smeeth, Harriet Forbes, Shah Ebrahim

Published in: BMC Cardiovascular Disorders | Issue 1/2014

Login to get access

Abstract

Background

There is strong evidence of reductions in major vascular events from statins across all cardiovascular risk categories. However, trials of statin therapy have provided conflicting results regarding statin use and type 2 diabetes (T2DM). We aimed to assess the effect of statins on T2DM development.

Method

We carried out a population-based cohort study using the Clinical Practice Research Datalink (CPRD), a database of computerized clinical records. Every patient aged 30–85 years old starting a statin between 1989 and 2009 was matched with up to five non-statin users. The observation period in CPRD ended in 31 December 2011. Cox proportional hazard regression was used to compare rates of T2DM between statin users and non-users, using propensity score method to adjust for systematic differences between groups.

Results

The study basis comprised 2,016,094 individuals, including 430,890 people who received a statin, matched to 1,585,204 people not prescribed a statin. Mean follow-up time was 5.43 years for statin users and 3.89 years for nonusers. During follow-up 130,395 individuals developed T2DM. Statin use was associated with an increased risk of T2DM (HR 1.57; 95% CI 1.54-1.59), which increases with longer duration of use. The increased risk was smaller among people with hypertension or cardiovascular disease and was only apparent after 5 or more years treatment with statins in these groups. Conversely, age-specific risk ratios decreased in older people.

Conclusions

Statin use is associated with an increased risk of T2DM. Our results suggest that the relative risk is higher among people without diagnosed hypertension or cardiovascular disease. These findings should be considered in the context of the observational nature of the data which is prone to bias and unmeasured confounding.
Appendix
Available only for authorised users
Literature
1.
go back to reference A Report from the American Heart Association: Heart Disease and Stroke Statistics—2013 Update. Circulation. 2013, 127: e6-e245.CrossRef A Report from the American Heart Association: Heart Disease and Stroke Statistics—2013 Update. Circulation. 2013, 127: e6-e245.CrossRef
2.
go back to reference European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012, 33: 1635-1701.CrossRef European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012, 33: 1635-1701.CrossRef
3.
go back to reference Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366 (9493): 1267-1278.CrossRef Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366 (9493): 1267-1278.CrossRef
4.
go back to reference Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376 (9753): 1670-1681.CrossRef Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376 (9753): 1670-1681.CrossRef
5.
go back to reference Cholesterol Treatment Trialists' (CTT) Collaborators: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012, 380 (9841): 581-590.CrossRef Cholesterol Treatment Trialists' (CTT) Collaborators: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012, 380 (9841): 581-590.CrossRef
6.
go back to reference Collaborators CTT'(CTT): Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012, 7 (1): e29849-Epub 2012 Jan 19CrossRef Collaborators CTT'(CTT): Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012, 7 (1): e29849-Epub 2012 Jan 19CrossRef
7.
go back to reference Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375 (9716): 735-742.CrossRefPubMed Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375 (9716): 735-742.CrossRefPubMed
8.
go back to reference Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011, 104 (2): 109-124.CrossRefPubMed Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011, 104 (2): 109-124.CrossRefPubMed
9.
go back to reference Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001, 103: 357-362.CrossRefPubMed Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001, 103: 357-362.CrossRefPubMed
10.
go back to reference Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359: 2195-2207.CrossRefPubMed Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359: 2195-2207.CrossRefPubMed
11.
go back to reference Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009, 32: 1924-1929.CrossRefPubMedPubMedCentral Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009, 32: 1924-1929.CrossRefPubMedPubMedCentral
12.
go back to reference Coleman CI, Reinhart K, Kluger J, White CM: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008, 24: 1359-1362.CrossRefPubMed Coleman CI, Reinhart K, Kluger J, White CM: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008, 24: 1359-1362.CrossRefPubMed
14.
go back to reference Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y: Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012 Jan 23, 172 (2): 144-152.CrossRefPubMed Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y: Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012 Jan 23, 172 (2): 144-152.CrossRefPubMed
15.
go back to reference Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, Chen TJ, Lin SJ, Chiang CE: Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012 Oct 2, 60 (14): 1231-1238.CrossRefPubMed Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, Chen TJ, Lin SJ, Chiang CE: Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012 Oct 2, 60 (14): 1231-1238.CrossRefPubMed
16.
go back to reference Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, De Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011, 305 (24): 2556-2564. 22CrossRefPubMed Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, De Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011, 305 (24): 2556-2564. 22CrossRefPubMed
17.
go back to reference Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM: Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013, 346: f2610-doi:10.1136/bmj.f2610CrossRefPubMedPubMedCentral Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM: Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013, 346: f2610-doi:10.1136/bmj.f2610CrossRefPubMedPubMedCentral
18.
go back to reference Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P: Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011, 57 (14): 1535-1545.CrossRefPubMed Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P: Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011, 57 (14): 1535-1545.CrossRefPubMed
19.
go back to reference Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB: Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s. The Framingham Heart Study. Circulation. 2006, 113: 2914-2918.CrossRefPubMed Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB: Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s. The Framingham Heart Study. Circulation. 2006, 113: 2914-2918.CrossRefPubMed
20.
go back to reference Chen L, Magliano J, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus—present and future perspective. Nat Rev Endocrinol. 2012, 8: 228-236.CrossRef Chen L, Magliano J, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus—present and future perspective. Nat Rev Endocrinol. 2012, 8: 228-236.CrossRef
21.
go back to reference Meigs JB, The Kelly West Award Lecture 2009: Epidemiology of Type 2 Diabetes and Cardiovascular Disease: Translation From Population to Prevention. Diabetes Care. 2010, 33: 1865-1871.CrossRefPubMedPubMedCentral Meigs JB, The Kelly West Award Lecture 2009: Epidemiology of Type 2 Diabetes and Cardiovascular Disease: Translation From Population to Prevention. Diabetes Care. 2010, 33: 1865-1871.CrossRefPubMedPubMedCentral
22.
go back to reference Key health statistics from general practice 1998: Analyses of Morbidity and Treatment Data, Including Time Trends, England and Wales. Series MB6 no. 2. 2000, London: Office for National Statistics Key health statistics from general practice 1998: Analyses of Morbidity and Treatment Data, Including Time Trends, England and Wales. Series MB6 no. 2. 2000, London: Office for National Statistics
23.
go back to reference Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigómez A: Validity of the general practice research database. Pharmacotherapy. 2003, 23: 686-689.CrossRefPubMed Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigómez A: Validity of the general practice research database. Pharmacotherapy. 2003, 23: 686-689.CrossRefPubMed
24.
go back to reference Van Staa T-P, Abenhaim L: The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf. 1994, 3: 15-21.CrossRef Van Staa T-P, Abenhaim L: The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf. 1994, 3: 15-21.CrossRef
25.
go back to reference Khan NF, Harrison SE, Rose PW: Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010, 60 (572): e128-e136.CrossRefPubMedPubMedCentral Khan NF, Harrison SE, Rose PW: Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010, 60 (572): e128-e136.CrossRefPubMedPubMedCentral
26.
go back to reference Rodríguez G, Pérez LA, Gutthann S: Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998, 45 (5): 419-425.CrossRef Rodríguez G, Pérez LA, Gutthann S: Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998, 45 (5): 419-425.CrossRef
27.
go back to reference Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ: Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010 Jan, 69 (1): 4-14.CrossRefPubMedPubMedCentral Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ: Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010 Jan, 69 (1): 4-14.CrossRefPubMedPubMedCentral
28.
go back to reference Brookhart M, Schneeweiss S, Rothman KJ, Glynn R, Avorn J, Sturner T: Variable selection for propensity score models. Am J Epidemiol. 2006, 163: 1149-1156.CrossRefPubMedPubMedCentral Brookhart M, Schneeweiss S, Rothman KJ, Glynn R, Avorn J, Sturner T: Variable selection for propensity score models. Am J Epidemiol. 2006, 163: 1149-1156.CrossRefPubMedPubMedCentral
29.
go back to reference Sturmer T, Rothman KJ, Avorn J, Glynn RJ: Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol. 2010, 172: 843-854.CrossRefPubMedPubMedCentral Sturmer T, Rothman KJ, Avorn J, Glynn RJ: Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol. 2010, 172: 843-854.CrossRefPubMedPubMedCentral
30.
go back to reference Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011, CD004816-doi:10.1002/14651858.CD004816.pub4, Issue 1 Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011, CD004816-doi:10.1002/14651858.CD004816.pub4, Issue 1
31.
go back to reference Weycker D, Nichols GA, O'Keeffe Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G: Excess risk of diabetes in persons with hypertension. J Diabetes Complications. 2009, 23 (5): 330-336.CrossRefPubMed Weycker D, Nichols GA, O'Keeffe Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G: Excess risk of diabetes in persons with hypertension. J Diabetes Complications. 2009, 23 (5): 330-336.CrossRefPubMed
32.
go back to reference Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. J Med N Eng. 2000, 342: 905-912.CrossRef Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. J Med N Eng. 2000, 342: 905-912.CrossRef
33.
go back to reference Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M, Burneck study: Population based incidence rates and risk factors for type 2 diabetes in white individuals. Diabetes. 2004, 53: 1782-1789.CrossRefPubMed Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M, Burneck study: Population based incidence rates and risk factors for type 2 diabetes in white individuals. Diabetes. 2004, 53: 1782-1789.CrossRefPubMed
34.
go back to reference Kannel WB: Blood pressure as a cardiovascular risk factor. J Am Med Assoc. 1996, 275: 1571-1576.CrossRef Kannel WB: Blood pressure as a cardiovascular risk factor. J Am Med Assoc. 1996, 275: 1571-1576.CrossRef
35.
go back to reference Kannel WB: Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens. 2000, 13: 3S-10S.CrossRefPubMed Kannel WB: Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens. 2000, 13: 3S-10S.CrossRefPubMed
36.
go back to reference Reaven GM, Chang H: Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens. 1991, 4: 34-38.PubMed Reaven GM, Chang H: Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens. 1991, 4: 34-38.PubMed
37.
go back to reference Reaven GM: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med. 1991, 21: 7S-12S.CrossRef Reaven GM: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med. 1991, 21: 7S-12S.CrossRef
38.
go back to reference Baker WL, Talati R, White CM, Coleman CI: Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2010, 87 (1): 98-107.CrossRefPubMed Baker WL, Talati R, White CM, Coleman CI: Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2010, 87 (1): 98-107.CrossRefPubMed
39.
go back to reference Koh KK, Sakuma I, Quon MJ: Differential metabolic effects of distinct statins. Atherosclerosis. 2011, 215: 1-8.CrossRefPubMed Koh KK, Sakuma I, Quon MJ: Differential metabolic effects of distinct statins. Atherosclerosis. 2011, 215: 1-8.CrossRefPubMed
40.
go back to reference Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T: Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006, 49: 1881-1892.CrossRefPubMed Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T: Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006, 49: 1881-1892.CrossRefPubMed
41.
go back to reference Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Bruham LR, Verchere CB, Hayden MR: Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia. 2010, 53: 1110-1119.CrossRefPubMed Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Bruham LR, Verchere CB, Hayden MR: Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia. 2010, 53: 1110-1119.CrossRefPubMed
42.
go back to reference Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007, 13: 340-347.CrossRefPubMed Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007, 13: 340-347.CrossRefPubMed
43.
go back to reference Brunham LR, Kruit JK, Hayden MR, Verchere CB: Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep. 2010 Feb, 10 (1): 55-60.CrossRefPubMed Brunham LR, Kruit JK, Hayden MR, Verchere CB: Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep. 2010 Feb, 10 (1): 55-60.CrossRefPubMed
44.
go back to reference Orozco LJ, Buchleitner AM, Gimenez Perez G, Roqué I, Figuls M, Richter B, Mauricio D: Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008, CD003054-doi:10.1002/14651858.CD003054.pub3, 3 Orozco LJ, Buchleitner AM, Gimenez Perez G, Roqué I, Figuls M, Richter B, Mauricio D: Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008, CD003054-doi:10.1002/14651858.CD003054.pub3, 3
45.
go back to reference Cardona-Morrell M, Rychetnik L, Morrell SL, Espinel PT, Bauman A: Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health. 2010, 10: 653-doi:10.1186/1471-2458-10-653CrossRefPubMedPubMedCentral Cardona-Morrell M, Rychetnik L, Morrell SL, Espinel PT, Bauman A: Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health. 2010, 10: 653-doi:10.1186/1471-2458-10-653CrossRefPubMedPubMedCentral
46.
go back to reference Ramlo-Halsted BA, Edelman SV: The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies. Clin Diab. 2000, 18 (2): 80-85. Ramlo-Halsted BA, Edelman SV: The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies. Clin Diab. 2000, 18 (2): 80-85.
47.
go back to reference Pani LN, Nathan DM, Grant RW: Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care. 2008, 31: 386-390.CrossRefPubMed Pani LN, Nathan DM, Grant RW: Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care. 2008, 31: 386-390.CrossRefPubMed
48.
50.
go back to reference Van Staa TJ, Smeeth L, SW Ng E, Goldacre B, Gulliford M: The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?. Heart Online First. 2013, doi:10.1136/heartjnl-2013-303698 Van Staa TJ, Smeeth L, SW Ng E, Goldacre B, Gulliford M: The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?. Heart Online First. 2013, doi:10.1136/heartjnl-2013-303698
Metadata
Title
Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink
Authors
Ana Filipa Macedo
Ian Douglas
Liam Smeeth
Harriet Forbes
Shah Ebrahim
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2014
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-14-85

Other articles of this Issue 1/2014

BMC Cardiovascular Disorders 1/2014 Go to the issue